The clinical impact of pharmacogenetics on the treatment of epilepsy.
about
Intercellular transfer of P-glycoprotein in human blood-brain barrier endothelial cells is increased by histone deacetylase inhibitors.Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistanceThe roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studiesCommon variants of KCNJ10 are associated with susceptibility and anti-epileptic drug resistance in Chinese genetic generalized epilepsiesComparison between the Amount of Environmental Change and the Amount of Transcriptome ChangeUpdate on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.Genetic testing in the epilepsies--report of the ILAE Genetics CommissionMolecular Genetics of Epilepsy: A Clinician's Perspective.Epilepsy: The future scenario.Expectations, validity, and reality in pharmacogenetics.Drosophila KCNQ channel displays evolutionarily conserved electrophysiology and pharmacology with mammalian KCNQ channels.MDR-1 and MRP2 Gene Polymorphisms in Mexican Epileptic Pediatric Patients with Complex Partial SeizuresAntiepileptic drug interactions - principles and clinical implications.Cellular localization and functional significance of CYP3A4 in the human epileptic brain.Use of antiepileptic drugs for hyperkinetic movement disorders.Gene-wide tagging study of the association between KCNT1 polymorphisms and the susceptibility and efficacy of genetic generalized epilepsy in Chinese population.Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogeneticsCorpora amylacea deposition in the hippocampus of patients with mesial temporal lobe epilepsy: A new role for an old gene?Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsyExploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgeryRelationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysisRead-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescentsInfluence of the SCN1A IVS5N + 5 G>A Polymorphism on Therapy with Carbamazepine for Epilepsy.RLIP76 Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients.Epilepsy pharmacogenetics.Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients.Association of SCN1A gene polymorphism with antiepileptic drug responsiveness in the population of Thrace, Greece.The effects of ABCC2 G1249A polymorphism on the risk of resistance to antiepileptic drugs: a meta-analysis of the literature.Management of the patient with medically refractory epilepsy.ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics?Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis.Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions.Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective.Treatment options for refractory and difficult to treat seizures: focus on vigabatrinSecond-generation antiepileptic drugs and pregnancy: a guide for clinicians.Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs.
P2860
Q27332363-6BC4E5C1-573B-4675-BAC7-C1B5ED49D374Q28540047-AD7ACC16-22A5-43C8-9512-2E3EBC56A31BQ28545116-92B13D28-4879-4C44-8764-35F883175042Q28546107-A86560C2-90CB-4E1F-80DF-BDCF07815A9FQ28551497-1469D62C-E81B-43E4-9A5D-62AEE4433A2AQ33664128-AE1A0980-C508-4F0D-8735-38B3F11A050FQ33794130-34F75C09-571E-4817-A691-6E98E1D3A670Q33795557-FA61C3FC-B7F4-4465-9EAC-DB4C9A727B69Q33810221-8FF2474C-5BA5-481D-9595-2A1306D23F3EQ33926313-82F9DA2D-7540-4C8F-9097-D79BEA0FBF84Q34018870-C09D7D73-6BD7-42A7-9363-9A06288F9E57Q34312249-04259198-E77B-4732-8ACE-D2BFA12E5336Q34402188-0C2B08FD-D36D-4175-B77E-4FB8B1B6E58BQ34669448-980523BA-B97E-4360-9BAA-3C6B1D3C5D4AQ34829294-630BDD40-E551-452C-BD2C-29D0EF1384AAQ35054372-863CB700-4CFA-4726-B750-9A362706456CQ35072901-7D72D1BC-88B9-4DEC-B12E-38CA775AF681Q35073480-C3308511-CBF8-4387-AE5B-AA0F4EE68856Q35073485-8FEA212E-5B09-4847-8468-935C32035C87Q35351731-E6E0D152-AA85-40F0-8109-8B3E7CDAD213Q35389422-5ECA0449-CDBF-4329-94FE-87F5DCA1B3FAQ36281662-7CFB4633-87AB-4B00-83DE-0026BEF20E1FQ36907558-89051AC8-979D-4800-9C67-B3E6CE7DCF6DQ36947636-9A3929E7-795C-44E3-9A11-2BEB794805EEQ37104987-C35C6B13-B9C9-4E4B-A12B-7E3222AF5A3EQ37181448-BF8612E3-76A2-446C-8EF9-A3634977C543Q37181571-E0F05FB4-4C9E-4CD7-B023-CB1470A637B2Q37486720-8765E1AB-8021-4271-A98B-2C9B3B63B07BQ37522302-6D79BEDA-A364-4841-85FF-048B27A0FC5AQ37549339-BEAC6FD7-628A-4054-A511-7D91564F7015Q37587940-DA6BB549-09FE-4C95-B62B-13C35DB7F8F3Q37642003-3D47CCC1-23E3-4428-B8B6-F96E5E58455DQ37658265-FC1E2804-10CC-43A0-B6B6-D5332AB663F4Q37851513-80EAC744-B0B5-4AB9-A32D-16BC7CF597E3Q37873934-18611C0F-24AD-42DF-97DE-A4C7A1648BD6Q37873936-B18D118A-6986-4F10-89B5-22370F2ADDE4Q37900131-BEE0F0C8-3683-4CA0-84F8-EBF7D79D3083Q37937441-0A16F339-42AB-4BB5-828E-140207B44504Q38014890-1DE7F7FA-A092-4529-AFEC-9ADC58676B5EQ38181565-6AAE78F0-61DD-41C0-B4E5-249CCEBA5DA8
P2860
The clinical impact of pharmacogenetics on the treatment of epilepsy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The clinical impact of pharmacogenetics on the treatment of epilepsy.
@en
The clinical impact of pharmacogenetics on the treatment of epilepsy.
@nl
type
label
The clinical impact of pharmacogenetics on the treatment of epilepsy.
@en
The clinical impact of pharmacogenetics on the treatment of epilepsy.
@nl
prefLabel
The clinical impact of pharmacogenetics on the treatment of epilepsy.
@en
The clinical impact of pharmacogenetics on the treatment of epilepsy.
@nl
P2093
P2860
P1433
P1476
The clinical impact of pharmacogenetics on the treatment of epilepsy.
@en
P2093
Dieter Schmidt
Ulrich Klotz
Wolfgang Löscher
P2860
P356
10.1111/J.1528-1167.2008.01716.X
P577
2008-07-08T00:00:00Z